Trial Search Results
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: Merck Sharp & Dohme Corp.
Stanford Investigator(s):
Intervention(s):
- Drug: Ertugliflozin
- Drug: Glipizide
Phase:
Phase 4
Eligibility
Inclusion Criteria:
- patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
surgery
- history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled
Exclusion Criteria:
- allergy or intolerance to interventional medication
- currently taking any anti-diabetic medication other than metformin
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elizabeth Zanley, MS, RD
(650) 665-9554